| Stage | GMED | % of rev | PTCT | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $790M | 100.00% | $361M | 100.00% | GMED ×2.19 |
| Gross profit | $548M | 69.42% | $341M | 94.47% | PTCT +25.1pp |
| Operating income | $182M | 23.10% | $149M | 41.32% | PTCT +18.2pp |
| Pre-tax income | $190M | 24.04% | $98M | 27.06% | PTCT +3.0pp |
| Net income | $152M | 19.20% | $83M | 23.16% | PTCT +4.0pp |
| Stage | GMED | PTCT | Gap · A − B |
|---|---|---|---|
| Revenue | $790M100.00% | $361M100.00% | GMED ×2.19 |
| Gross profit | 69.42%$548M | 94.47%$341M | PTCT +25.1pp |
| Operating income | 23.10%$182M | 41.32%$149M | PTCT +18.2pp |
| Pre-tax income | 24.04%$190M | 27.06%$98M | PTCT +3.0pp |
| Net income |
| 19.20%$152M |
| 23.16%$83M |
| PTCT +4.0pp |
None
No disclosed counterparties: GMED.